{
    "clinical_study": {
        "@rank": "21550", 
        "arm_group": [
            {
                "arm_group_label": "Histoacryl group", 
                "arm_group_type": "Active Comparator", 
                "description": "the injected agents consisted of n-butyl-2-cyanoacrylate (Histoacryl; B.Braun, Melsungen AG, Germany) 0.5ml mixed with 1.5 ml Lipiodol ultra-fluide (Guerbet, Bois Cedex, France). The injection site was aimed at the bleeding varices or varices with red color signs or at the most prominent varices."
            }, 
            {
                "arm_group_label": "thrombin group", 
                "arm_group_type": "Experimental", 
                "description": "Among the thrombin group, the injection site was also aimed at the bleeding varices or varices with red color signs or at the most prominent varices. The injected agents consisted of lyophilized human Thrombin in calcium chloride solution containing thrombin 500IU/ml). (Floseal, Baxter Healthcare Corporation, CA, Hayward, USA)"
            }
        ], 
        "brief_summary": {
            "textblock": "Though histoacryl injection is now regarded as treatment of choice in the control of gastric\n      variceal hemorrhage, it may be associated with a lot of complications such as ulcers, ulcer\n      bleeding, bacterial infections, distant site thrombosis and cerebral vascular accident. On\n      the other hand, thrombin has been shown to be effective in acute hemostasis of bleeding\n      gastric varices, ranging from 70% to 100% has been recorded. The rebleeding rates were\n      between 7% and 50%. Moreover, the benefits of thrombin injection include safety, without\n      inducing ulcers or ulcer bleeding. No incidence of distant thrombosis has ever been\n      reported."
        }, 
        "brief_title": "A Prospective, Randomized Trial of Histoacryl Injection Versus Thrombin in the Control of Acute Gastric Variceal Bleeding", 
        "condition": [
            "Ulcer, on Gastric Varices", 
            "Rebleeding From Gastric Varices"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Esophageal and Gastric Varices", 
                "Hemorrhage", 
                "Varicose Veins"
            ]
        }, 
        "detailed_description": {
            "textblock": "Previous studies have proven that the use of cyanoacrylate glue injection was superior to\n      EIS or EVL in arresting acute gastric variceal bleeding. Endoscopic obturation with glue\n      injection has gained worldwide popularity except the United States. The hemostatic rates of\n      glue injection ranged from 87% to 100%, with rebleeding rates about 7% to 71%.\n\n      Though histoacryl injection is now regarded as treatment of choice in the control of gastric\n      variceal hemorrhage, it may be associated with a lot of complications such as ulcers, ulcer\n      bleeding, bacterial infections, distant site thrombosis and cerebral vascular accident. On\n      the other hand, thrombin has been shown to be effective in acute hemostasis of bleeding\n      gastric varices, ranging from 70% to 100% has been recorded. The rebleeding rates were\n      between 7% and 50%. Moreover, the benefits of thrombin injection include safety, without\n      inducing ulcers or ulcer bleeding. No incidence of distant thrombosis has ever been\n      reported. The mechanism of hemostasis induced by thrombin is through the conversion of\n      fibrinogen to fibrin and enhancement of platelets aggregation. This trial aimed to compare\n      the relative efficacy and safety between histoacryl injection and thrombin injection in the\n      prevention of gastric variceal rebleeding."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  1.The etiology of portal hypertension is cirrhosis. 2.Age ranges between 20-80 y/o.\n             3.Patients presenting with history of gastric variceal bleeding or acute gastric\n             variceal bleeding proven by emergency endoscopy\n\n        Exclusion Criteria:\n\n          -  1) association with severe systemic illness, such as sepsis,  CVA, COPD,  advanced\n             carcinoma, hepatocellular carcinoma (Barcelona Club Liver Cancer class C or D) 2)\n             presence of massive ascites 3), serum creatinine \uff1e3mg/dl, hepatic encephalopathy >\n             stage II, 4) serum bilirubin > 10mg/dl 5) life expectancy less than 24 hours 6)\n             Child-Pugh's scores > 13 7) pregnancy  8) has ulcers on gastric varices 9)\n             Uncooperative"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "62", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01717612", 
            "org_study_id": "Thrombin study"
        }, 
        "intervention": [
            {
                "arm_group_label": "thrombin group", 
                "description": "Among the thrombin group, the injection site was also aimed at the bleeding varices or varices with red color signs or at the most prominent varices. The injected agents consisted of lyophilized human Thrombin in calcium chloride solution containing thrombin 500IU/ml). (Floseal, Baxter Healthcare Corporation, CA, Hayward, USA)", 
                "intervention_name": "Thrombin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Histoacryl group", 
                "description": "The injection site was aimed at the bleeding varices or varices with red color signs or at the most prominent varices.", 
                "intervention_name": "Histoacryl", 
                "intervention_type": "Drug", 
                "other_name": "n-butyl-2-cyanoacrylate"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Thrombin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "gastric varices, thrombin, histoacryl", 
        "lastchanged_date": "November 2, 2012", 
        "location": {
            "contact": {
                "email": "ghlo@kimo.com", 
                "last_name": "Gin-Ho Lo, M.D", 
                "phone": "886-7-6150011", 
                "phone_ext": "1629"
            }, 
            "facility": {
                "address": {
                    "city": "Kaohsiung", 
                    "country": "Taiwan", 
                    "zip": "824"
                }, 
                "name": "E-DA Hospital"
            }, 
            "investigator": {
                "last_name": "Gin-Ho Lo, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Prospective, Randomized Trial of Histoacryl Injection Versus Thrombin in the Control of Acute Gastric Variceal Bleeding", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Taiwan: Department of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "ulcer crater or ulcer with bleeding from gastric varices", 
            "measure": "Ulcer on gastric varices", 
            "safety_issue": "Yes", 
            "time_frame": "1 month after therapy"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01717612"
        }, 
        "responsible_party": {
            "investigator_affiliation": "E-DA Hospital", 
            "investigator_full_name": "Gin-Ho Lo", 
            "investigator_title": "Vice Superintendent, E-DA Hospital", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "rebleeding from gastric varices", 
            "measure": "rebleeding", 
            "safety_issue": "No", 
            "time_frame": "6 weeks"
        }, 
        "source": "National Science Council, Taiwan", 
        "sponsors": {
            "collaborator": {
                "agency": "E-DA Hospital", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "National Science Council, Taiwan", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}